Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers
Cancer Medicine · 2025
DOI: 10.1002/cam4.70615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von William Jacot und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Biomarkers, Tumor, Cell Adhesion Molecules. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo, inc, Daiichi Sankyo Europe.
Abstract (Originalsprache)
Introduction
Triple‐Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell‐surface antigen‐2 (Trop‐2), using antibody‐drug conjugates (ADC), results in significant clinical improvement. However, clinicopathological correlations with Trop‐2 protein expression levels remain limited in TNBC patients.
Methods
Here we assessed by immunohistochemistry (IHC) using the mouse monoclonal anti‐Trop‐2 antibody (Enzo, Cat. ENZ‐ABS380) cell membrane Trop‐2 expression levels and classified them in 3 H‐Score classes, low (< 100), moderate (100–200), and strong (> 200). We also evaluated potential associations with clinicopathological variables including basal‐like and molecular apocrine phenotypes, immune infiltrate characteristics, PTEN and PIK3CA alterations in a large retrospective series of 228 nonmetastatic TNBC patients.
Results
Trop‐2 expression was evaluated as low, moderate and strong in 12.3%, 28.9%, and 58.8% of the cases respectively. Only 3 tumors showed no Trop‐2 expression. Interestingly, Trop‐2 expression was not associated with classical breast cancer clinicopathological variables, HER2 levels or molecular subtype, neither did we observe an association with relapse‐free survival. Only a marginal association with pT1 tumors was observed, which tended to express increased levels of Trop‐2 protein. In order to determine possible fluctuations of Trop‐2 protein expression levels during the course of the disease, we studied a second independent cohort of 18 TNBC comprised of serial tissue samples (diagnostic biopsies, surgical resection specimens and corresponding patients‐derived xenografts (PDX)). Trop‐2 levels remained globally stable between cognate tumor samples with only one exception corresponding to a Trop‐2‐negative tumor giving rise to a Trop‐2‐positive PDX.
Conclusions
As Trop‐2 expression appears nearly constant and independent of classical TNBC variables and outcome, association of anti‐Trop‐2 therapies with other targeted therapies can be evaluated without reducing the population in specific TNBC subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.
- Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.
- Montpellier University, Montpellier, France.
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France.
- Biometrics Unit, Institut du Cancer Montpellier (ICM), Université de Montpellier, Montpellier, France.
- Institut du Cancer Montpellier (ICM), Université de Montpellier, Montpellier, France.
ORCID-Profile: William Jacot, Charles Theillet
Förderung
- Daiichi Sankyo, inc
- Daiichi Sankyo Europe
Zitieren
APA
Jacot, W., Chateau, M. C., Thezenas, S., Guiu, S., Firmin, N., Lafont, V., Lazennec, G., Theillet, C., & Boissière-Michot, F. (2025). Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers. Cancer Medicine. https://doi.org/10.1002/cam4.70615
Vancouver
Jacot W, Chateau MC, Thezenas S, Guiu S, Firmin N, Lafont V, et al. Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers. Cancer Medicine. 2025. doi:10.1002/cam4.70615
BibTeX
@article{Jacot2025,
author = {Jacot, William and Chateau, Marie-Christine and Thezenas, Simon and Guiu, Séverine and Firmin, Nelly and Lafont, Virginie and Lazennec, Gwendal and Theillet, Charles and Boissière-Michot, Florence},
title = {Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70615}
}
EUVIMED